Talaris Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Mary Fenton
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 20.6% |
| CEO tenure | 2.6yrs |
| CEO ownership | 0.07% |
| Management average tenure | no data |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?
May 24
Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?
Feb 14We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
Oct 21Talaris drops 24% after patient death in late-stage trial for lead asset
Oct 20Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk
Aug 29Talaris Therapeutics GAAP EPS of -$0.44
Aug 15We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
Jul 06Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial
Jun 30Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans
Mar 23Talaris Therapeutics EPS beats by $0.49
Jun 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$75m |
| Mar 31 2023 | n/a | n/a | -US$78m |
| Dec 31 2022 | US$2m | US$455k | -US$74m |
| Sep 30 2022 | n/a | n/a | -US$70m |
| Jun 30 2022 | n/a | n/a | -US$64m |
| Mar 31 2022 | n/a | n/a | -US$57m |
| Dec 31 2021 | US$2m | US$340k | -US$48m |
Compensation vs Market: Mary's total compensation ($USD2.21M) is about average for companies of similar size in the US market ($USD2.23M).
Compensation vs Earnings: Mary's compensation has been consistent with company performance over the past year.
CEO
Mary Fenton (59 yo)
2.6yrs
Tenure
US$2,209,223
Compensation
Ms. Mary Kay Fenton has been Chief Financial Officer at Talaris Therapeutics, Inc. since March 2021 and serves as its Treasurer and has been its Interim CEO and President since May 26, 2023. She had been a...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 21.7yrs | US$1.33m | 11.88% $ 65.7m | |
| Independent Director | 4.9yrs | US$130.42k | 0% $ 0 | |
| Independent Director | 4.9yrs | US$135.05k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$137.92k | 0% $ 0 | |
| Independent Chairman | 4.9yrs | US$175.92k | 0.90% $ 5.0m | |
| Independent Director | 4.9yrs | US$130.42k | 0% $ 0 | |
| Independent Director | 1.4yrs | US$249.58k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$126.92k | 0% $ 0 |
4.9yrs
Average Tenure
56yo
Average Age
Experienced Board: TALS's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/21 15:36 |
| End of Day Share Price | 2023/10/19 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Talaris Therapeutics, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Evercore ISI |
| Debjit Chattopadhyay | Guggenheim Securities, LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |